Allarity Therapeutics Appoints Jeffrey Ervin as Full-Time CFO

TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off The latest announcement is out from Allarity Therapeutics ( (ALLR) ). On December 3, 2025, Allarity Therapeutics, Inc. transitioned Jeffrey S. Ervin from a part-time to a full-time Chief Financial Officer role under a new employment agreement. This agreement includes an annual base salary of $367,700, restricted stock units, and a performance bonus, reflecting the company’s commitment to strengthening its financial leadership. The most recent analyst rating on (ALLR) stock is a Buy with a $9.25 price target. To see the full list of analyst forecasts on Allarity Therapeutics stock, see the ALLR Stock Forecast page. Spark’s Take on ALLR Stock According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform. Allarity Therapeutics’ overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal. To see Spark’s full report on ALLR stock, click here. More about Allarity Therapeutics Allarity Therapeutics, Inc. operates in the biotechnology industry, focusing on developing and commercializing innovative oncology therapeutics. Average Trading Volume: 378,765 Technical Sentiment Signal: Sell Current Market Cap: $18.01M